Degroof Petercam - Hyloris Pharmaceuticals (HYL) Hyloris Pharma - Kicking off 2024 with a new asset

Report

Degroof Petercam

David Seynnaeve, PhD

Hyloris Pharma - Kicking off 2024 with a new asset

*Last night, HYL announced the addition of an asset ‘HY-091' for inflammatory disease ‘vulvar lichen sclerosus' (VLS). The drug candidate will be developed and commercialized in partnership with AFT Pharmaceuticals.*3 weeks in the new year, the company has now 21 assets in the pipeline/portfolio: 9 more to go to reach their 2025 target of 30 assets.*No impact on valuation or investment case for the time being. Buy reiterated.

19/01/2024 1 EN

Underlying

Hyloris Pharmaceuticals

See profile

BE0974363955 Euronext Brussels Belgium

Provider

Degroof Petercam

We are an investment house with Belgian roots founded on more than 150 years of trust.

As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.

See profile

Analysts

David Seynnaeve, PhD

Other Reports on these Companies

KBC Securities

Morning Notes : ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HYL BB, IBAB BB, KIN BB, MTLS US, VGP BB, AZE BB, ZEAL DC

: ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HYL BB, IBAB BB, KIN BB, MTLS US, VGP BB, AZE BB, ZEAL DC

February 19, 2026 February 19, 2026 1 EN

KBC Securities

Hyloris Valacyclovir oral suspension is delayed

Hyloris provided an update regarding the review of valacyclovir for oral suspension which had a PDUFA target action date of 12 October 2025. It appears that the FDA identified significant inspection observations at the third party manufacturing plant in Greece. The manufacturer confirmed that it is actively implementing its remediation plans. Currently, Hyloris believes that resolution of the manufacturing situation is required to obtain an FDA product approval and is working on a solution. We reiterate our € 6 TP and Hold rating.

February 19, 2026 February 19, 2026 1 EN

KBC Securities

Morning Notes : ARCAD NA, GIMB BB, HYL BB, CTPNV NA

: ARCAD NA, GIMB BB, HYL BB, CTPNV NA

January 20, 2026 January 20, 2026 1 EN

(Sponsored) Cabka - Extracting full value from recent investments

New 2-phase strategy. At its recent CMD, Cabka announced a two-phase strategy. First strengthening the company with deleveraging of the balance sheet and an EBITDA margin recovery to 13-15%, followed by an expansion phase in which organic growth and acquisitions can drive revenues to EUR >300m, with the EBITDA-margin exceeding 15%.More defensive approach. After several difficult years, Cabka is choosing a more defensive approach, reinforcing its balance sheet while taking calculated risks with new product introductions to drive growth. The near-term focus is on cost control and capital efficie...

November 25, 2025 November 25, 2025 1 EN

Luuk Van Beek

Luuk Van Beek

EnergyVision - Profitable green energy with a sunny growth outlook

Unique model with stable high marginsStable return by matching production and consumption. EnergyVision has developed a unique model based on green solar energy, where it matches production and consumption to create attractive stable returns. Its long-term contracts with consumers give it good visibility on the prices at which it sells its solar energy. Customers benefit from attractive prices and lower vulnerability to future price hikes.EV chargers bring even better matching. With the launch of chargers for electric vehicles in 2022, EnergyVision has added another sales channel for its solar...

August 22, 2025 August 22, 2025 1 EN

Luuk Van Beek

Luuk Van Beek

(Sponsored) Fastned - Gearing up for a growth spurt

Scaling up its succesful station approachRolling out tried-and-tested concept. Fastned is a clear market leader in highway fast charging in the Netherlands. In the past years it has optimized its concept to provide market-leading reliability and a high service level to customers at competitive costs. It is now rolling out this concept to other European countries, aiming to grow from 346 stations at YE2024 to 1,000 stations by 2030.Significant operating leverage. The stations have been operating at a positive operating EBITDA (i.e. before network expansion costs) since 2019 and their total EBIT...

July 3, 2025 July 3, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Hyloris Pharma - Kicking off 2024 with a new asset

Morning Notes : ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HYL BB, IBAB BB, KIN BB, MTLS US, VGP BB, AZE BB, ZEAL DC

Hyloris Valacyclovir oral suspension is delayed

Morning Notes : ARCAD NA, GIMB BB, HYL BB, CTPNV NA

(Sponsored) Cabka - Extracting full value from recent investments

EnergyVision - Profitable green energy with a sunny growth outlook

(Sponsored) Fastned - Gearing up for a growth spurt

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe